Gilead's Epclusa: FDA Sought To Push Efficacy Bar Higher In Hepatitis C

Drug Review Profile of the pan-genotypic HCV treatment shows agency staff debating whether fixed-dose combination's strong efficacy in certain genotype 3 patients could be further maximized by adding ribavirin.